Breast Cancer
Conditions
Brief summary
The purpose of this study is to determine whether UTD1 Injection in combination with capecitabine is effective in the treatment of advanced metastatic breast cancer using capecitabine as a control.
Interventions
DRUGUTD1 Injection plus capecitabine
DRUGCapecitabine
Sponsors
Beijing Biostar Pharmaceuticals Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Histologically and/or cytologically diagnosed patients with advanced, metastatic breast cancer,or lacking standard therapy or being failed to or recurrent after standard therapy; 2. Patients who have previously treated with ≤4 chemotherapeutic regimes; 3. Patients who have previously treated with an anthracyclin antibiotics and a taxane; 4. Age 18 -70 years old, ECOG performance status of 0-2; Life expectancy of 3 months or more; 5. Patients with at least 1 measurable target lesion determined by CT within 2 weeks prior to enrollment; 6. Neuropathy \<CTC2 degree （NCI CTC4.03）within 4 weeks prior to enrollment; 7. Basically normal results from routine blood test within 1 week prior to enrollment; 8. Basically normal liver and renal functions within 1 week prior to enrollment; 9. No abnormal function for major internal organs, no heart diseases.
Exclusion criteria
1. Received chemotherapy, radiotherapy, therapies with hormones or molecularly targeted drugs 4 weeks prior to enrollment, or received other chemotherapies while participating in this trial; 2. Patients with documented hypersensitivity to Cremophor EL, or patients with previous taxane treatment related SAE; 3. Patients of pregnancy or breast feeding; 4. Patients with previous standard capecitabine treatment ineffective, or patients received standard capecitabine treatment effective, but with less than 6 months of capecitabine clearance period; 5. Patients with uncontrolled brain metastasis or bone metastasis, which plan for recent surgery or local radiotherapy, or other emergency treatment; 6. Patients combined with severe and /or uncontrolled medical conditions, including severe cardiovascular disease, uncontrolled diabetes and high blood pressure, severe infection, severe gastrointestinal ulceration, and patients with incontrollable psychiatric history; 7. Patients with poor compliance; 8. Patients not fitted for this study determined by the investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progresssion free survival (PFS) | 2.0 years |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival (OS) | 4 years |
| Objective Response Rate(ORR） | 1.5 years |
Countries
China
Outcome results
None listed